Worldwide Digital & Computational Pathology Market Forecasted to Grow at 15% p.a., Reaching $1.75B by 2028 – Market Report by DeciBio Consulting LLC

May 11, 2023
DeciBio News
Clinical Diagnostics

Worldwide Digital & Computational Pathology Market Forecasted to Grow at 15% p.a., Reaching $1.75B by 2028 – Market Report by DeciBio Consulting LLC


Los Angeles, CA

May 11, 2023

DeciBio Consulting LLC’s latest market report, “Digital & Computational Pathology Market Report 2023-2028,” states that the global digital pathology market, driven by continued use across pharma and increased use in clinical settings, is predicted to reach $1.75B by 2028.

The first edition of DeciBio’s digital and computational pathology (D&CP)report takes a comprehensive look at the global D&CP products and services market landscape, summarizing both present and future (2023-2028) use. Informed by a combination of primary research, secondary research, and proprietaryDeciBio databases and tools, this report provides a quantitative and qualitative assessment of key segments (e.g., customer type, products and services, technology, application, geography, and therapeutic area). In addition, this report details market drivers (e.g., increased acceptance of slide scanners in the clinical setting), moderators (e.g., high cost of instruments and software), trends (e.g., interest in using image analysis andAI tools), and profiles of top players in the space.

Digital pathology (DP) refers to the digitization and digital interpretation of pathology slides, including slide scanning, as well as the use of image management systems, workflow software, image analysis and AI tools, and data storage. Computational pathology (CP) utilizes artificial intelligence and machine learning to enable analysis of morphological, single plex, and multiplex signatures. Biopharma has been the largest customer segment ofD&CP to date, however, use in the clinic is growing, with widespread access to DP infrastructure in leading academic medical centers (AMCs) and reference labs, and growing adoption in mid-sized hospitals.

Learn more about DeciBio’s Digital & Computational Pathology Market Report 2023-2028:

Digital Pathology Companies Mentioned:

  • 3D Histech
  • 4D Path
  • AetherAI
  • Agilent
  • Aiforia
  • Aira Matrix
  • Akoya Biosciences
  • Augmentiqs
  • Aurora mScope
  • Corista
  • Deep Bio
  • Epredia
  • Evident
  • Fujifilm / Inspirata
  • Gestalt
  • Glencoe Software
  • Grundium
  • Hamamatsu
  • Huron Digital Pathology
  • Ibex
  • Imagene
  • Indica Labs
  • Infinitt
  • Leica Microsystems
  • Lumea
  • Lunit
  • Mikroscan
  • Mindpeak
  • Morphle
  • Motic
  • Nikon
  • Nucleai
  • Objective Imaging
  • OptraScan
  • Owkin
  • Paige
  • PathAI
  • Pathcore
  • PathPresenter
  • Philips
  • Pramana
  • Precipoint
  • PreciseDx
  • PredxBio
  • Proscia
  • Prospective Imaging Services
  • Reveal Biosciences
  • Roche
  • Sectra
  • Scopio
  • Smart in Media Intelligent Software
  • Sunquest
  • Techcyte
  • Tempus
  • Tribun Health
  • Ultivue
  • Visiopharm
  • Zeiss

Digital Pathology Market Analysis:

Market Drivers

Emerging interest in the use of AI for image analysis, improvements in both hardware and software capabilities, as well as the realization of workflow efficiencies, will spur greater adoption of digital pathology and drive market growth. Pharma has driven a significant portion of the market to-date, which is expected to continue as they apply digital pathology tools toward companion diagnostic development and for patient selection in clinical trials. Clinical use is currently fragmented, providing a strong growth opportunity, as larger institutions expand their digitized pathology labs and new placements are made at small and mid-sized hospitals.

Market Moderators

Barriers persist to market entry and further development in the Digital Pathology field.Interoperability challenges across solutions from different providers make integration difficult, regardless of customer type, and limits scalability. Cost of implementation, coupled with a lack of specific reimbursement, will continue to gate access, especially in clinical settings. Lastly, a generational gap slows current adoption by senior pathologists, serving as a roadblock to wide spread uptake.

Precision Medicine is evolving at a rapid pace

Discover how we can help

Get in Touch